DLA Piper advises Heron Therapeutics on sale of substantially all assets to CorMedix...
11 November 2026 .2 minute read
DLA Piper advises IMVIONIX on US and Canadian commercial rights for retinal therapy
10 November 2026 .2 minute read
Inside Competition: November 2026
10 November 2026 .17 minute read